Drug intelligence / Profile preview

docetaxel + cabazitaxel

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of two taxane chemotherapeutic agents that are often used sequentially in the treatment of prostate cancer, particularly in cases of hormone-refractory metastatic disease. Both drugs function as microtubule inhibitors, binding to tubulin and promoting its assembly into microtubules while simultaneously inhibiting disassembly, which leads to the stabilization of microtubules and inhibition of cellular functions. Typically, docetaxel is used as first-line therapy, and when disease progresses during or after docetaxel treatment, cabazitaxel is administered as a second-line option.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + cabazitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + cabazitaxel.

Explore the full profile